Navigation Links
Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDF's 20th World Diabetes Congress
Date:10/21/2009

MONTREAL, Oct. 21 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes. Data from the Phase 2 dose optimization study, which were used to determine the dose in the DEFEND trial, were presented at the International Diabetes Federation's 20th World Diabetes Congress currently taking place in Montreal, Canada.

In an oral presentation entitled "Otelixizumab - Dose regimen optimization of a humanized aglycosylated anti-CD3 monoclonal antibody in adult subjects with type 1 diabetes mellitus," Dr. Louis Vaickus, Chief Medical Officer at Tolerx, presented preliminary data from the Phase 2 otelixizumab dose optimization clinical study, referred to as TTEDD.

In a previous investigator-sponsored Phase 2 study, a high dose (48-64 mg) of otelixizumab was shown to preserve natural insulin production for up to 48 months after a single course of treatment. Subsequently, Tolerx initiated TTEDD to investigate alternative dosing regimens that would minimize adverse events, while maintaining durable clinical activity. A cumulative dose of 3.1 mg of otelixizumab administered over 8 days was identified as the optimized dose suitable for further evaluation. In TTEDD, this dosing regimen resulted in preservation of beta cell function (as measured by C-peptide, a common marker for endogenous insulin production) for up to 12 months in patients with autoimmune new-onset type 1 diabetes with no observation of significant safety issues.

About the DEFEND Study

DEFEND (Durable Response Therapy Evaluation
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tolerx Announces Amendment to Phase 3 DEFEND Protocol
2. Tolerx Expands Phase 3 DEFEND Trial of Otelixizumab in Europe
3. Laureate Announces Manufacturing Agreement with Tolerx
4. Tolerx Named as One of the Fierce 15 Biotech Companies of 2008
5. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
6. AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show
7. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
8. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
9. NovaBay(R) Presents Data Confirming Its Aganocide(R) Compounds Are Effective In Killing Bacteria That Have Developed Multidrug-Resistance
10. Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco
11. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... it will hold its 2015 Annual Meeting of Stockholders ... Because the expected date for the Annual Meeting represents ...
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 ... webinar series is designed to introduce cutting ... inform users and partners of platform upgrades. ... and benefits; empowering users in their quest ... powerful tools. , According to SoundConnect’s Marketing ...
(Date:12/24/2014)... Nashville Fertility Center announced that ... the American Society for Reproductive Medicine (ASRM), a leading ... reproductive medicine. In his new role as treasurer, ... board and will have a voice in furthering the ... supported ASRM since 1984 when he joined while conducting ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... FLEMINGTON, N.J. , June 24 Beardsworth Consulting ... as the company,s Scientific Advisor, Oncology and Robert W. Malone , ... , , ... oncology,s respected research leaders with over 20 years of clinical research experience. ...
... HOPKINTON, Mass. , June 25 Caliper Life Sciences, ... services for drug discovery and life sciences research, hosted its 2010 ... and 10. This thought-leadership conference is focused on sharing knowledge, ... leading to the next generation of breakthrough diagnostics and therapies. , ...
... BERLIN , June ... worldwide by 10 to 20 percent per year through ... accelerate R&D and,commercialization in this nascent industry, making it ... market demand. Representatives from,Germany Trade & Invest will be ...
Cached Biology Technology:Alison Martin, MD and Robert W. Malone, MD Join Beardsworth 2Caliper Owners Group Meeting Showcases Critical Role of Biopharma and Academic Researchers for Improving Healthcare and Quality of Life 2Caliper Owners Group Meeting Showcases Critical Role of Biopharma and Academic Researchers for Improving Healthcare and Quality of Life 3Market Demand and Innovation in Germany Propel Industrial Biotechnology Growth 2Market Demand and Innovation in Germany Propel Industrial Biotechnology Growth 3
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ... long-held beliefs about the condition and the best ways to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... introduced to regions beyond their native range carry ... are responsible for the loss of natural resources and biodiversity, ... Not all non-native species pose a threat. Scientists around the ... conditions that set the stage for debilitating invaders, like ...
... The Dead Sea, a salt sea without an outlet, ... its high salt content because it increases their buoyancy. ... popular archive that provides a diachronic view of its ... Steinmann-Institute for Geology, Mineralogy and Paleontology at the University ...
... framework to evaluate the risk of resistance for the ... this work: A framework for assessing the risk of ... the Malaria Journal today. Resistance ... is important when developing new medicines for malaria, to ...
Cached Biology News:Losing stream in our battle to predict and prevent invasive species 2Losing stream in our battle to predict and prevent invasive species 3Drastic desertification 2Drastic desertification 3MMV develops framework to assess risk of resistance for antimalarial compounds 2
... derived from Paraffin embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 5 ... are large (3-5mm in diameter) in comparison ...
... Precision-designed for Optimal Microdissection , CapSure ... the precise and rapid extraction of populations ... cytology samples with Laser Capture Microdissection., ... Downstream Molecular Analysis , All CapSure LCM ...
... The new MyiQ real-time PCR detection ... detection of common green fluorescent dyes such ... system interfaces directly with the iCycler thermal ... gradient and Peltier-effect driven performance. The MyiQ ...
... are highly sensitive laser confocal systems designed ... advanced scanners that meet your expectations, differentiating ... and optimizing the signal on the bottom ... the range for increased sensitivity. Results with ...
Biology Products: